Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Lonza Group    LONN   CH0013841017

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
07/17/2017 07/18/2017 07/19/2017 07/20/2017 07/21/2017 Date
215.9(c) 214.4(c) 217.5(c) 216.7(c) 216.3 Last
204 442 230 075 316 248 345 971 211 928 Volume
+0.65% -0.69% +1.45% -0.37% -0.18% Change
More quotes
Financials ( CHF)
Sales 2017 4 977 M
EBIT 2017 870 M
Net income 2017 534 M
Debt 2017 3 430 M
Yield 2017 1,26%
Sales 2018 5 757 M
EBIT 2018 1 100 M
Net income 2018 756 M
Debt 2018 2 673 M
Yield 2018 1,48%
P/E ratio 2017 27,13
P/E ratio 2018 21,55
EV / Sales2017 3,93x
EV / Sales2018 3,27x
Capitalization 16 137 M
More Financials
Company
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products.It operates its business through the Pharma&Biotech and Specialty Ingredients segments.The Pharma&Biotech segment deals with the supply of pharmaceutical ingredients and biopharmaceuticals as well as... 
More about the company
Surperformance© ratings of Lonza Group
Trading Rating : Investor Rating :
More Ratings
Latest news on LONZA GROUP
07/20 LONZA : Data Integrity for Endotoxin Testing” – New FAQs Released to..
07/06 Lonza Completes Acquisition of Capsugel to Create Leading Integrated Solution..
07/06 LONZA : Completes Acquisition of Capsugel to Create Leading Integrated Solutions..
06/29 Global 3D Cell Culture Market 2017- Thermo Fisher Scientific, Corning, Lonza ..
06/27 LONZA : CHRO Elected to Board of Advance Women in Swiss Business
06/27 Lonza Has Received All Regulatory Approvals to Move Forward with Acquisition ..
06/27 LONZA : Has Received All Regulatory Approvals to Move Forward with Acquisition o..
06/26 LONZA : Gallucci to Lead Sales & Marketing, Americas, for Lonza's Personal Care ..
06/13 Lonza Prices CHF 235 Million Dual Tranche Straight Bonds
06/13 LONZA : Prices CHF 235 Million Dual Tranche Straight Bonds
More news
Sector news : Biotechnology & Medical Research - NEC
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/12 FDA panel backs Novartis' pioneering new cancer gene therapy
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
07/19Lonza Group Ag upgraded by Jefferies Group LLC to buy.  
07/19Lonza Group Ag upgraded by Jefferies Group LLC to buy.  
07/06KKR Completes Sale of Capsugel to Lonza and Distributes Proceeds to All Emplo.. 
07/06Samsung BioLogics seeks to nullify Lonza’s cell line tech patent in Korea #Sa.. 
06/27Lonza : CHRO Elected to Board of Advance Women in Swiss Business  
More tweets
Qtime:55
News from SeekingAlpha
06/27 TIGENIX : This Stem Cell Pioneer Is Up 40% Since IPO With More Upside To Come
05/08 G1 Therapeutics Proposes Terms For $100 Million IPO
04/27 G1 Therapeutics Seeks $115 Million IPO
03/17 Lonza Tied To Attractive Markets
03/16 Catalent's Price Is A Little Hard To Swallow
Chart LONZA GROUP
Duration : Period :
Lonza Group Technical Analysis Chart | LONN | CH0013841017 | 4-Traders
Technical analysis trends LONZA GROUP
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 212  CHF
Spread / Average Target -1,9%
EPS Revisions
Managers
NameTitle
Richard Ridinger Chief Executive Officer
Rolf Soiron Chairman
Marc Funk Chief Operating Officer
Rodolfo Savitzky Chief Financial Officer
Patrick Aebischer Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP33.19%16 967
INCYTE CORPORATION33.43%27 397
QUINTILES IMS HOLDINGS INC19.61%19 489
CELLTRION, INC.--.--%12 547
ALKERMES PLC3.51%8 813
QIAGEN NV18.74%7 975